Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide
Status:
Completed
Trial end date:
2003-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of nitrocamptothecin plus etoposide in
treating patients who have advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
Astex Pharmaceuticals Astex Pharmaceuticals, Inc. National Cancer Institute (NCI)
Treatments:
Camptothecin Etoposide Etoposide phosphate Rubitecan Topoisomerase I Inhibitors